Literature DB >> 26201943

Bone involvement in males with Kallmann disease.

Giovanni Iolascon1, Laura Frizzi2, Massimiliano Bianco2, Francesca Gimigliano3, Vincenzo Palumbo4, Antonia Maria Sinisi4, Antonio Agostino Sinisi4,5.   

Abstract

BACKGROUND: Kallmann syndrome (KS) is a rare genetic condition characterized by congenital early-onset hypogonadotropic hypogonadism and anosmia or hyposmia. Male subjects are more frequently affected and present absent/delayed puberty, low testosterone levels with higher risk for osteoporosis. Therefore, to maintain normal levels of sex steroids and prevent bone loss, male KS needs life-long hormonal replacement therapy (HRT). AIMS: The objective of our study is to assess bone involvement in subjects with KS currently treated with HRT.
METHODS: In our retrospective study, we analyzed data from medical records of patients with KS treated with HRT (either gonadotropins or testosterone preparations), including clinical history, biochemical parameters, and the following outcome measures: the bone mineral density (BMD) at the lumbar spine (LS), femoral neck (FN), and total body less head (TBLH); and the Vertebral Fracture Assessment (VFA) by Dual Energy X-ray Absorptiometry (DXA).
RESULTS: Clinical and instrumental data of 32 patients with KS were evaluated; their mean age was 30.32 (± 10.09) years, their mean body mass index (BMI) was 25.71 (± 3.23) kg/m(2). Four patients (12.5%) had a LS BMD Z score below the expected range for age. Five patients had vertebral deformities observed at VFA. Duration of HRT was related to bone health parameters: BMD at all measured sites were higher in patients receiving adequate HRT for more than 2 years compared with the patients treated for less than 6 months. A deficient vitamin D status was found in 43% of cases and it was prevalent in patients with shorter HRT. DISCUSSION AND
CONCLUSION: Early starting and adequate duration of HRT are related to bone health parameters in patients with congenital hypogonadotropic hypogonadism due to KS. Restoring vitamin D sufficiency might also be advisable in this condition.

Entities:  

Keywords:  Hormone replacement therapy; Hypogonadotropic hypogonadism; Kallmann syndrome; Osteoporosis

Mesh:

Substances:

Year:  2015        PMID: 26201943     DOI: 10.1007/s40520-015-0421-5

Source DB:  PubMed          Journal:  Aging Clin Exp Res        ISSN: 1594-0667            Impact factor:   3.636


  4 in total

Review 1.  Male Hypogonadism and Osteoporosis: The Effects, Clinical Consequences, and Treatment of Testosterone Deficiency in Bone Health.

Authors:  Gary Golds; Devon Houdek; Terra Arnason
Journal:  Int J Endocrinol       Date:  2017-03-16       Impact factor: 3.257

Review 2.  Dental-craniofacial manifestation and treatment of rare diseases.

Authors:  En Luo; Hanghang Liu; Qiucheng Zhao; Bing Shi; Qianming Chen
Journal:  Int J Oral Sci       Date:  2019-02-20       Impact factor: 6.344

3.  Reply to Jakovac: About COVID-19 and vitamin D.

Authors:  Angelo Facchiano; Antonio Facchiano; Manuela Bartoli; Alberto Ricci; Francesco Facchiano
Journal:  Am J Physiol Endocrinol Metab       Date:  2020-06-01       Impact factor: 4.310

4.  Clinical characteristics of 138 Chinese female patients with idiopathic hypogonadotropic hypogonadism.

Authors:  Rui-Yi Tang; Rong Chen; Miao Ma; Shou-Qing Lin; Yi-Wen Zhang; Ya-Ping Wang
Journal:  Endocr Connect       Date:  2017-10-10       Impact factor: 3.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.